NCT05844501View on ClinicalTrials.gov

Ondansetron for the Management of Atrial Fibrillation

PHASE4RecruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

April 22, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions
Atrial Fibrillation
Interventions
DRUG

Ondansetron 8mg

Ondansetron 8 mg orally twice daily for 28 days

DRUG

Placebo

Matched placebo orally twice daily for 28 days

Trial Locations (3)

46202

RECRUITING

Indiana Clinical Research Center, Indianapolis

NOT_YET_RECRUITING

Indiana University Health Methodist Hospital, Indianapolis

RECRUITING

Purdue University, Indianapolis

All Listed Sponsors
collaborator

American Heart Association

OTHER

collaborator

Purdue University

OTHER

lead

Indiana University

OTHER